BioAge Reports Positive Phase 1 Data For BGE-102 Showing Up To 86% hsCRP Reduction With Favorable Safety, Plans Phase 2 Cardiovascular Trial In 2026

Benzinga Newsdesk www.benzinga.com Positive 89.2%